Description: Danletro tablets for oral administration contains 2.5mg of letrozole, a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis). Letrozole is a white to yellowish crystalline powder, practically odorless, freely soluble in dichloromethane, slightly soluble in ethanol, and practically insoluble in water.
Indication:
First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.
Adjuvant treatment of oestrogen receptor positive invasive early breast cancer in postmenopausal women.
Advanced breast cancer in postmenopausal women (naturally or artificially induced menopause) in whom other antiestrogen therapy has failed.
Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received standard adjuvant tamoxifen therapy for 5 years.
Neo adjuvant treatment in postmenopausal women with localized hormone receptor positive, human epidermal growth factor-2 negative breast cancer where chemotherapy is not suitable and surgery not yet indicated.